June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA. ABECMA (idecabtagene vicleucel). https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel (2021).

FDA. BREYANZI (lisocabtagene maraleucel). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel (2021).

FDA. KYMRIAH (tisagenlecleucel). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel (2021).

FDA. TECARTUS (brexucabtagene autoleucel). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel (2021).

FDA. YESCARTA (axicabtagene ciloleucel). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel (2021).

FDA. CARVYKTI (ciltacabtagene autoleucel). https://www.fda.gov/vaccines-blood-biologics/carvykti (2022).

Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342–355 (2022).

Article  PubMed  Google Scholar 

Logue, J. M. et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica 106, 978–986 (2021).

Article  CAS  PubMed  Google Scholar 

Uy, N. F. et al. Hypogammaglobulinemia and infection risk in chronic lymphocytic leukemia (CLL) patients treated with CD19-directed chimeric antigen receptor T (CAR-T) cells. Blood 136, 30–32 (2020).

Article  Google Scholar 

Schubert, M. L. et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann. Oncol. 32, 34–48 (2021).

Article  CAS  PubMed  Google Scholar 

Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489–503.e8 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castellarin, M. et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI Insight 5, e136012 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Smith, J. B. et al. Tumor regression and delayed onset toxicity following B7-H4 CAR T cell therapy. Mol. Ther. 24, 1987–1999 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Labanieh, L. et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185, 1745–1763 (2022).

Article  CAS  PubMed  Google Scholar 

Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).

Article  PubMed  Google Scholar 

Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells–a completed study overview. Biochem. Soc. Trans. 44, 951–959 (2016).

Article  CAS  PubMed  Google Scholar 

Feng, K.-C. et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J. Hematol. Oncol. 10, 4 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Guo, Y. et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin. Cancer Res. 24, 1277–1286 (2018).

Article  CAS  PubMed  Google Scholar 

Liu, Y. et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy 22, 573–580 (2020).

Article  PubMed  Google Scholar 

Feng, K. et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell 9, 838–847 (2018).

Article  CAS  PubMed  Google Scholar 

Thistlethwaite, F. C. et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol. Immunother. 66, 1425–1436 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, Y. et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. J. Cancer Res. Clin. Oncol. 147, 3725–3734 (2021).

Article  CAS  PubMed  Google Scholar 

Richman, S. A. et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol. Res. 6, 36–46 (2018).

Article  CAS  PubMed  Google Scholar 

Davenport, A. J. et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc. Natl Acad. Sci. USA 115, E2068–E2076 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meiraz, A., Garber, O. G., Harari, S., Hassin, D. & Berke, G. Switch from perforin-expressing to perforin-deficient CD8+ T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo. Immunology 128, 69–82 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong, L. K. et al. CD30-redirected chimeric antigen receptor T cells target CD30+ and CD30- embryonal carcinoma via antigen-dependent and Fas/FasL interactions. Cancer Immunol. Res. 6, 1274–1287 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benmebarek, M.-R. et al. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci. 20, 1283 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dufva, O. et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood 135, 597–609 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Schietinger, A. et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314, 304–308 (2006).

Article  CAS  PubMed  Google Scholar 

Wong, A. J. et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl Acad. Sci. USA 89, 2965–2969 (1992).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Posey, A. D. Jr et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44, 1444–1454 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heitzeneder, S. et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell 40, 53–69.e9 (2021).

Article  PubMed  Google Scholar 

Bosse, K. R. et al. Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell 32, 295–309.e12 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith, C. C. et al. Alternative tumour-specific antigens. Nat. Rev. Cancer 19, 465–478 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).

Article  CAS  PubMed  Google Scholar 

Li, G. & Wong, A. J. EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev. Vaccines 7, 977–985 (2008).

Article  PubMed  Google Scholar 

O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Vitanza, N. A. et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat. Med. 27, 1544–1552 (2021).

Article  CAS  PubMed